Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modular Layer-by-Layer Nanoparticle Platform for Hematopoietic Progenitor and Stem Cell Targeting.

Tamara G Dacoba1, Namita Nabar1,2, Paula T Hammond1,2,3,4

  • 1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States.

ACS Nano
|March 13, 2025
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polymer Molecular Weight Influences Cancer Cell Surface Retention and Cytokine Presentation by Layer-by-Layer Nanoparticles.

ACS nano·2026
Same author

A multivalent peptide-polymer conjugate material mimics STING to therapeutically activate innate immune signaling.

bioRxiv : the preprint server for biology·2026
Same author

Leveraging tissue-resident memory T cells for non-invasive immune monitoring via microneedle skin patches.

Nature biomedical engineering·2026
Same author

Subcellular nanoparticle trafficking investigated with label-free, live cell imaging.

Nanoscale horizons·2026
Same author

Cationic Antimicrobial Carbon Acid Polymer Eradicates <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> Biofilms.

ACS applied materials & interfaces·2026
Same author

Ether lipids influence cancer cell fate by modulating iron uptake.

Nature communications·2026

This study introduces novel layer-by-layer nanoparticles (LbL NPs) for targeted drug and gene delivery to hematopoietic stem and progenitor cells (HSPCs). These engineered nanoparticles show promise for improved therapies in blood disorders by enhancing HSPC targeting and reducing off-target effects.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Hematology

Background:

  • Effective drug and gene delivery to hematopoietic stem and progenitor cells (HSPCs) remains a significant challenge for treating genetic disorders and hematological malignancies.
  • Current therapies face limitations including high costs, limited accessibility, and significant off-target toxicities.
  • Layer-by-layer nanoparticles (LbL NPs) offer a modular approach with tunable surface properties for precise cellular targeting.

Purpose of the Study:

  • To develop and characterize antibody-functionalized LbL NPs for targeted delivery to HSPCs.
  • To evaluate the specificity and efficiency of LbL NPs in targeting HSPCs while minimizing uptake by other cell types.
  • To assess the potential of LbL NPs for disease-specific targeting in hematological malignancies.

Main Methods:

Keywords:
hematological malignancieshematopoietic stem cellsin vivo targetingstealth nanoparticlestargeting

Related Experiment Videos

  • Fabrication of LbL NPs using poly(acrylic acid) and antibody functionalization (anti-cKit, anti-CD90, anti-CD105, anti-CXCR4).
  • In vitro assessment of NP uptake by nondifferentiated bone marrow cells.
  • In vivo evaluation of NP association with HSPCs and progenitor subpopulations in mice.
  • Adaptation of the LbL NP platform for targeting human CD34+ cells and human cancer cell lines.

Main Results:

  • Poly(acrylic acid)-based LbL NPs exhibited enhanced stealth properties in vivo.
  • Anti-cKit and anti-CD90 conjugation increased NP uptake in vitro by 2- to 3-fold.
  • Anti-CD105 functionalized NPs demonstrated the highest in vivo association with HSPCs (3.0–8.5%).
  • Anti-CXCR4 functionalization showed significant targeting of human B-cell lymphoma and leukemia cells.

Conclusions:

  • The developed LbL NP platform is modular and can be engineered for specific targeting of HSPCs.
  • Antibody selection is crucial for optimizing targeting efficiency and minimizing off-target effects.
  • This technology holds therapeutic potential for HSPC-related diseases, with disease-dependent targeting capabilities.